StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)

Close on Nov 17, 2026Market cap $109.97MP/E –Yield –

LENZ Therapeutics price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

LENZ Therapeutics's price to book ratio was 0.6× on Nov 11, 2026, against 4.5× a year earlier. Over the last 4 years it ranged from 0.1× to 6.4×, with a median of 1.0×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.6×−1.8
2025Dec 31, 20252.4×−1.3
2024Dec 31, 20243.7×+3.6
2023Jan 31, 20230.1×−0.1
2022Dec 30, 20220.1×−0.3
2021Dec 31, 20210.4×–

More LENZ Therapeutics figures

See a number that looks wrong?